Medpark unveils 5th year plan, aims for “Hospital for treating difficult and complex diseases, targeting 4,000 billion in revenue”

Medpark sets 5th year strategy to build brand for hospital for treating difficult diseases, MOU with Chinese-Thai partners to study T-cells-genomes, initially invests 40 million baht to open a cancer biopsy lab by early next year, targeting 67 billion baht in revenue in 4, foreign patients increase to 30%

October 21, 2567 Private hospital market in 2567 Krungthai COMPASS estimates that it will expand within the range of 8-12% per year. It is considered to be slower than 2564-2565 at 13.4-31.8%, supported by the following factors: The number of patients and the rate of illness are increasing. The society is aging. “The complexity of the disease” That is more

Dr. Phongphat Patanawanit, Managing Director Medpark Hospital

Dr. Pongpat Patanwanich, Managing Director Medpark Hospital (MedPark) It was revealed that Medpark Hospital is preparing to enter its 5th year and its key strategy is to position itself as a hospital that treats difficult and complex diseases with the expertise of 120 full-time specialists and 800-1,000 part-time specialists.

Medpark initially plans to sign a Memorandum of Understanding (MOU) with Beijing Medical University to study and exchange medical knowledge about cancer and immunity, in order to plan treatment for patients with related diseases.

With an investment budget of no less than 40 million baht, it will establish a medical genome center and open a laboratory center to facilitate faster treatment, such as analyzing tissue samples from patients to determine whether they have cancer or not, with results available in 2 weeks, compared to the original 6-week process of sending them to labs abroad. Both Thai and foreign certificates will be issued together. In addition, this center will also study human immune genomes, and is expected to open for service in early 2568.

Meanwhile, Medpark Hospital has conducted research in collaboration with Chulalongkorn University and Ramathibodi Hospital to study CAR-T cells, with Chulalongkorn and Ramathibodi Hospital being the manufacturers and using the treatment area in Medpark, which will have a positive effect in the future on investment in the development of such treatment centers.

“In the past, Medpark focused on groups of people who could not diagnose diseases or complicated diseases such as heart disease, organ transplants, bone marrow transplants, etc.”

However, in the past, Medpark Hospital has had an outpatient base of more than 400,000 people, due to the COVID period when free vaccinations were provided to both Thais and foreigners. If classified by nationality, the main proportion is Thais, approximately 90%, and foreigners, 10%, mainly from the Middle East and CLMV countries (Cambodia, Laos, Myanmar, and Vietnam), including Expats.

“From the trend of service recipients, it reflects that some are more widely aware of the positioning of Med Park in the treatment of difficult diseases. For the target in 2567, it is expected to generate income of 4,000 billion baht, growing from the previous year by more than 3,000 billion baht, and targeting to increase the proportion of foreign patients to 30% from the original 10%.”

Read all interesting business news here.